New classes of potent heparanase inhibitors from ligand-based virtual screening

References

• Li JP, Kusche-Gullberg M. Heparan sulfate: biosynthesis, structure, and function. Int Rev Cell Mol Biol 2016;325:215–73.
   PubMed Web of Science ®Google Scholar
• Billings PC, Pacifici M. Interactions of signaling proteins, growth factors and other proteins with heparan sulfate: mechanisms and mysteries. Connect Tissue Res 2015;56:272–80.
   PubMed Web of Science ®Google Scholar
• Fux L, Ilan N, Sanderson RD, Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem Sci 2009;34:511–9.
   PubMed Web of Science ®Google Scholar
• Rivara S, Milazzo FM, Giannini G. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem 2016;8:647–80.
   PubMed Web of Science ®Google Scholar
• Jin H, Zhou S. The functions of heparanase in human diseases. Mini Rev Med Chem 2017;17:541–8.
   PubMed Web of Science ®Google Scholar
• Ramani VC, Vlodavsky I, Ng M, et al. Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biol 2016;55:22–34.
   PubMed Web of Science ®Google Scholar
• Vlodavsky I, Singh P, Boyango I, et al. Heparanase: from basic research to therapeutic applications in cancer and inflammation. Drug Resist Updat 2016;29:54–75.
   PubMed Web of Science ®Google Scholar
• Ferro V. Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses. Expert Opin Ther Targets 2013;17:965–75.
   PubMed Web of Science ®Google Scholar
• Mohan CD, Hari S, Preetham HD, et al. Targeting heparanase in cancer: inhibition by synthetic, chemically modified, and natural compounds. iScience 2019;15:360–90.
   PubMed Web of Science ®Google Scholar
• Liao BY, Wang Z, Hu J, et al. PI-88 inhibits postoperative recurrence of hepatocellular carcinoma via disrupting the surge of heparanase after liver resection. Tumour Biol 2016;37:2987–98.
   PubMedGoogle Scholar
• Dredge K, Brennan TV, Hammond E, et al. A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. Br J Cancer 2018;118:1035–41.
   PubMed Web of Science ®Google Scholar
• Galli M, Chatterjee M, Grasso M, et al. Phase I study of the heparanase inhibitor Roneparstat: an innovative approach for multiple myeloma therapy. Haematologica 2018;103:e469–e472.
   PubMed Web of Science ®Google Scholar
• O'Reilly EM, Roach J, Miller P, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: phase I results. Oncologist 2017;22:1429–e139.
   PubMed Web of Science ®Google Scholar
• Fu K, Bai Z, Chen L, et al. Antitumor activity and structure-activity relationship of heparanase inhibitors: recent advances. Eur J Med Chem 2020;193:112221.
   PubMed Web of Science ®Google Scholar
• Pan W, Miao HQ, Xu YJ, et al. [4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors. Bioorg Med Chem Lett 2006;16:409–12.
   PubMed Web of Science ®Google Scholar
• Xu Y, Miao H, Pan W, Navarro EC, et al. N-(4-{[4-(1H-Benzoimidazol-2-yl)-arylamino]-methyl}-phenyl)-benzamide derivatives as small molecule heparanase inhibitors. Bioorg Med Chem Lett 2006;16:404–8.
   PubMed Web of Science ®Google Scholar
• Courtney SM, Hay PA, Buck RT, et al. Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor. Bioorg Med Chem Lett 2005;15:2295–9.
   PubMed Web of Science ®Google Scholar
• Courtney SM, Hay PA, Buck RT, et al. 3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors. Bioorg Med Chem Lett 2004;14:3269–73.
   PubMed Web of Science ®Google Scholar
• Madia VN, Messore A, Pescatori L, et al. Novel benzazole derivatives endowed with potent anti-heparanase activity. J Med Chem 2018;61:6918–36.
   PubMed Web of Science ®Google Scholar
• Messore A, Madia VN, Pescatori L, et al. Novel symmetrical benzazolyl derivatives endowed with potent anti-heparanase activity. J Med Chem 2018;61:10834–59.
   PubMed Web of Science ®Google Scholar
• Rondanin R, Fochi S, Baruchello R, et al. Arylamidonaphtalene sulfonate compounds as a novel class of heparanase inhibitors. Bioorg Med Chem Lett 2017;27:4421–5.
   PubMed Web of Science ®Google Scholar
• Sola F, Farao M, Ciomei M, et al. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis. Invasion Metastasis 1995;15:222–31.
   PubMedGoogle Scholar
• Nakajima M, DeChavigny A, Johnson CE, et al. Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem 1991;266:9661–6.
   PubMed Web of Science ®Google Scholar
• https://www.emolecules.com/
   Google Scholar
• https://www.cas.org/products/scifinder
   Google Scholar
• Duan J, Dixon SL, Lowrie JF, Sherman W. Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods. J Mol Graph Model 2010;29:157–70.
   PubMed Web of Science ®Google Scholar
• Sastry M, Lowrie J, Dixon SL, Sherman W. Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments. J Chem Inf Model 2010;50:771–84.
   PubMed Web of Science ®Google Scholar
• Canvas, version 2.6. New York (NY): Schrödinger, LLC; 2015.
   Google Scholar
• Chen X, Reynolds CH. Performance of similarity measures in 2D fragment-based similarity searching: comparison of structural descriptors and similarity coefficients. J Chem Inf Model 2002;42:1407–14.
   Google Scholar
• Flower DR. On the properties of bit string-based measures of chemical similarity. J Chem Inf Model 1998;38:379–86.
   Google Scholar
• Wu L, Viola CM, Brzozowski AM, Davies GJ. Structural characterization of human heparanase reveals insights into substrate recognition. Nat Struct Mol Biol 2015;22:1016–22.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2015-4: Glide. New York (NY): Schrödinger, LLC; 2015.
   Google Scholar
• Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–9.
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2015 − 4. Maestro. New York (NY): Schrödinger, LLC; 2015.
   Google Scholar
• Schrödinger Release 2015 − 4. LigPrep. New York (NY): Schrödinger, LLC; 2015.
   Google Scholar
• Deng Z, Chuaqui C, Singh J. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. J Med Chem 2004;47:337–44.
   PubMed Web of Science ®Google Scholar
• Singh J, Deng Z, Narale G, Chuaqui C. Structural interaction fingerprints: a new approach to organizing, mining, analyzing, and designing protein-small molecule complexes. Chem Biol Drug Des 2006;67:5–12.
   PubMed Web of Science ®Google Scholar
• Murtagh F, Contreras P. Algorithms for hierarchical clustering: an overview. WIREs Data Mining Knowl Discov 2012;2:86–97.
   Web of Science ®Google Scholar
• Hammond E, Li CP, Ferro V. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening. Anal Biochem 2010;396:112–6.
   PubMed Web of Science ®Google Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112–6.
   PubMed Web of Science ®Google Scholar
• Ayal-Hershkovitz M, Miron D, Levy O, Benz-1,3-azole derivatives, their preparation, and their uses as heparanase inhibitors. WO02060374; 2002.
   Google Scholar
• Simeonovic C, Parish CR, Ziolkowski A, Heparanase inhibitors for the inhibition of degradation of extracellular matrix associated with islet β-cells. WO2008046162; 2008.
   Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719–40.
   PubMed Web of Science ®Google Scholar
• Levy-Adam F, Abboud-Jarrous G, Guerrini M, et al. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. J Biol Chem 2005;280:20457–66.
   PubMed Web of Science ®Google Scholar
• Nardella C, Lahm A, Pallaoro M, et al. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 2004;43:1862–73.
   PubMed Web of Science ®Google Scholar
• Ishida K, Hirai G, Murakami K, et al. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. Mol Cancer Ther 2004;3:1069–77.
   PubMed Web of Science ®Google Scholar
• Zetser A, Bashenko Y, Miao HQ, et al. Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 2003;63:7733–41.
   PubMed Web of Science ®Google Scholar
• Cassinelli G, Lanzi C, Tortoreto M, et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol 2013;85:1424–32.
   PubMed Web of Science ®Google Scholar
• Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta, Rev Cancer 2001;1471:M99–M108.
   PubMed Web of Science ®Google Scholar
• Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006;38:2018–39.
   PubMed Web of Science ®Google Scholar
• Schubert SY, Ilan N, Shushy M, et al. Human heparanase nuclear localization and enzymatic activity. Lab Invest 2004;84:535–44.
   PubMed Web of Science ®Google Scholar
• Chen L, Sanderson RD. Heparanase regulates levels of syndecan-1 in the nucleus. PLoS One 2009;4:e4947.
   PubMed Web of Science ®Google Scholar
• He YQ, Sutcliffe EL, Bunting KL, et al. The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes. Transcription 2012;3:130–45.
   PubMedGoogle Scholar
• Piccolo P, Iqbal O, Demir M, et al. Global anticoagulant effects of a novel sulfated pentomanan oligosaccharide mixture. Clin Appl Thromb Hemost 2001;7:149–52.
   PubMed Web of Science ®Google Scholar
• Baburajeev CP, Mohan CD, Rangappa S, et al. Identification of novel class of triazolo-thiadiazoles as potent inhibitors of human heparanase and their anticancer activity. BMC Cancer 2017;17:235.
   PubMed Web of Science ®Google Scholar
• Swetha H, Swaroop TR, Preetham HD, et al. Synthesis, cytotoxic and heparanase inhibition studies of 5-oxo-1-arylpyrrolidine-3-carboxamides of hydrazides and 4-amino-5-aryl-4H-1,2,4-triazole-3-thiol. J Org Synth 2020; 17:243–50.
   Google Scholar